Insulet Corporation · NASDAQ:PODD
Insulet — Baird 2024 Global Healthcare Conference
10 slides from Insulet's conference presentation, Sep 10, 2024
Slide 1: Insulet Corporation – Baird 2024 Global Healthcare Conference
Morgan Kimsue Podder Podder since 2019 since 2023 Insulet Corporation Baird 2024 Global Healthcare Conference September 10, 2024 Eric Benjamin – EVP, Chief Product & Customer Experience Officer Ana Chadwick – EVP, Chief Financial Officer and Treasurer Deborah Gordon – VP, Investor Relations
Slide 2: Forward Looking Statement and Non-GAAP Financial Measures
Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on current expectations and beliefs concerning future developments a
Slide 3: Achieving Our Mission with Market-Leading Innovation
Achieving Our Mission with Market-Leading Innovation Our Mission is to improve the lives of people with diabetes and enable our customers to enjoy simplicity, Shepherd & Emmett freedom, and healthier lives through Market-Leading Podders since 2023 Technology innovative technology Omnipod Reduce Impr
Slide 4: Well Positioned for the Large Market Opportunity
Well Positioned for the Large Market Opportunity 25 Countries Offering Omnipod ~14M TAM1 Across Markets in Different Stages of Maturity Non-pump users Pump users ~ 3.5 ~3.5 ~ 3.0 + ~2.5 ~ 1.5 ~40% ~20% 20% ~5% 42% 2 U.S. T1D Current U.S. T2D 3 U.S. T2D Current Int’l T1D Basal-Bolus Basal-Only Int’l
Slide 5: Strong Fundamentals Powering Financial Results
Strong Fundamentals Powering Financial Results Revenue Gross Profit & Margin (adjusted)1 Operating Income & Margin (adjusted)1 $s in Billions $s in Billions $s in Millions $2.5 $1.6 $300 14.0% +390 bps +720 bps 22% CAGR Expansion 69.0% $2.0 $1.4 Expansion $250 $2.0 67.7% $1.7 $1.2 12.3% $200 $1.5 $1
Slide 6: Q2 Updates and Growth Catalysts
Q2 Updates and Growth Catalysts Q2’24 Financial Highlights1 Recent Catalysts • Revenue: $488.5M, up 23.4% in constant currency2 • U.S. launch of Omnipod 5 for people with type 2 diabetes (510(k) clearance received August 26, 2024) • Gross Margin: 67.7%, up 90 bps3 • Integration with Dexcom’s G7 sens
Slide 7: Thank You
Christian Podder since 2020 Thank Thank You You
Slide 8: Appendix
Appendix Insulet
Slide 9: Reconciliation of Non-GAAP Measures
Reconciliation of Non-GAAP Measures Quarter Ended June 30, Revenue 2024 2023 Percent Change Currency Impact Constant Currency U.S. Omnipod $352.3 $276.8 27.3% -% 27.3% International Omnipod 128.1 103.7 23.5% (0.9)% 24.4% Total Omnipod 480.4 380.5 26.3% (0.2)% 26.5% Drug Delivery 8.1 16.0 (49.4)% -%
Slide 10: Reconciliation of Non-GAAP Measures
Reconciliation of Non-GAAP Measures FY 2023 % of FY 2022 % of FY 2020 % of Revenue Revenue Revenue Gross Profit $ 1,159.9 68.3% $ 805.6 61.7% $ 582.3 64.4% Voluntary MDCs1 (11.5) 57.9 — Adjusted Gross Profit $ 1,148.4 67.7% $ 863.5 66.2% $ 582.3 64.4% Operating Income $ 220.0 13.0% $ 37.6 2.9% $ 51.